Kornimate/medical-research-clean huggingface dataset:
a study to assess the effect of ketoconazole on the metabolism of abt-263 (navitoclax).

Conditions: Lymphoma; Chronic Lymphocytic Leukemia; Solid Tumors

Summary: this is a single dose, open-label, single or multiple center study to determine the interaction of ketoconazole with abt-263 in approximately 12 subjects with cancer.


Eligibility criteria:
inclusion criteria: * 18 years of age or older. * has a non-hematologic malignancy (radiographic, histologic, or cytologic confirmation), or hematologic malignancy (histologic or cytologic confirmation) that is either: relapsed or refractory to standard therapy, failed at least one prior therapy or no known effective therapy exists. * in the investigator's opinion, the subject's life expectancy is at least 90 days. * if clinically indicated, (e.g., subjects over the age of 70) subjects must have documented brain imaging (mri or ct) negative for subdural or epidural hematoma within 28 days prior to the first dose of study drug. * subjects with brain metastases must have clinically controlled neurologic symptoms, defined as surgical excision and/or radiation therapy followed by 21 days of stable neurologic function and no evidence of cns disease progression as determined by ct or mri within 21 days prior to the first dose of study drug. exclusion criteria: * history of or is clinically suspicious for cancer-related central nervous system (cns) disease. * has undergone an allogeneic stem cell transplant. * has an underlying, predisposing condition of bleeding or currently exhibits signs of bleeding. * has active peptic ulcer disease or other hemorrhagic esophagitis/gastritis. * has active immune thrombocytopenic purpura or a history of being refractory to platelet transfusions (within 1 year prior to the first dose of study drug). * significant history of cardiovascular disease (e.g., mi, thrombotic or thromboembolic event in the last 6 months), renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, or hepatic disease. female subject is pregnant or breast-feeding. * history of or an active medical condition(s) that affects absorption or motility (e.g., crohn's disease, celiac disease, gastroparesis, short bowel syndrome, etc). * exhibits evidence of other clinically significant uncontrolled condition(s) including, but not limited to: active systemic fungal infection; diagnosis of fever and neutropenia within one week prior to study drug administration. * received any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal (with the exception of hormones for hypothyroidism or estrogen replacement therapy \[ert\], or agonists required to suppress serum testosterone levels \[e.g., lhrh, gnrh, etc.\] for subjects with prostate cancer * currently receiving or requires anticoagulation therapy or any drugs or herbal supplements that affect platelet function. * currently receiving or requires anti-fungal treatment or cyp3a inhibitors. in the opinion of the investigator, the subject is an unsuitable candidate to receive abt-263. * history of or is clinically suspicious for cancer-related central nervous system (cns) disease.
chronic mycoprotein consumption and nucleotide content in metabolic health

Conditions: Healthy

Summary: compare chronic (one week) of a 'normal' meat diet with one week of mycoprotein consumption, with or without a reduced nucleotide content, on markers of metabolic health, such as uric acid concentrations, blood glucose control and blood lipid profiles.


Eligibility criteria:
inclusion criteria: * bmi between 18 and 30 exclusion criteria: * on medication (except contraception) * smokers * diagnosed with any metabolic or cardiovascular conditions * bmi \ 30 * dietary restrictions (vegetarians/vegans, etc.)
observational of adjuvant treatment of breast cancer with liposomal doxorubicin regimen

Conditions: Breast Cancer; Liposomal Doxorubicin; Efficacy; Safety; Postoperative Adjuvant Treatment

Summary: the goal of this observational study aims to observe and evaluate the efficacy and safety of a liposomal doxorubicin containing regimen in the postoperative adjuvant treatment of breast cancer patients.


Eligibility criteria:
inclusion criteria: 1. female, aged 18-75 years; 2. primary breast cancer diagnosed histopathologically; 3. adjuvant chemotherapy regimens include liposomal doxorubicin; 4. ecog ps score: 0-1 points; 5. left ventricular ejection fraction (lvef) ≥ 55%; 6. estimated survival ≥ 6 months; 7. major organ function is normal, i.e. meets the following criteria: ① and white blood cells ≥ 4.0 × 10 9 / l, neutrophil count (anc) ≥ 1.5 × 10 9 /l；② platelets ≥ 100 × 10 9 /l；③ and hemoglobin ≥ 10 g / dl; ④ serum creatinine ≤ 1.5 × ⑤ the upper limit of normal (uln) mmol / l and aspartate transaminase (ast) ≤ 2.5 × uln；⑥ alanine transaminase (alt) ≤ 2.5 × uln；⑦ total bilirubin ≤ 1.5 × uln；⑧ serum creatinine ≤ 1.5 × uln； 8. subjects voluntarily join this study, sign the informed consent form, have good compliance and cooperate with follow-up. exclusion criteria: 1. pregnant, lactating patients; 2. breast cancer has been found to have distant metastasis; 3. those with peripheral nervous system disorders caused by the disease or with a history of significant mental disorders and central nervous system disorders; 4. those with severe infection or active peptic ulcer requiring treatment; 5. allergic to chemotherapy drugs; 6. cancer free period less than 5 years except for cured basal cell carcinoma of the skin and cured carcinoma in situ of the cervix; 7. severe liver disease (e.g., cirrhosis, etc.), renal disease, respiratory disease, or uncontrolled diabetes; 8. patients who are participating in other clinical trials or within a month.
safety study of recombinant human alpha-mannosidase for the treatment of patients with alpha-mannosidosis

Conditions: Alpha Mannosidosis

Summary: this is a single-center, open-label, dose escalation study of patients with alpha-mannosidosis. 10 patients will be enrolled in this study receiving intravenous infusions of lamazym. in order to avoid development of delayed hypersensitivity all patients will continue weekly treatment at the designated dose until the safety committee approves transfer to the rhlaman-03 protocol. it is the hypothesis that lamazym is safe to use.


Eligibility criteria:
inclusion criteria: 1. the patient must have a confirmed diagnosis of alpha-mannosidosis as defined by alpha-mannosidase activity \< 10% of normal activity in blood leukocytes 2. the patient must have an age at the time of screening ≥ 5 year and ≤ 20 years 3. the patient must have physical ability to perform 6-minutes walk test (6mwt), 3 minute-stair climb test (3msct) and pulmonary lung function test (spirometry, body plethysmography). 4. the patient must have the ability to mentally cooperate in the cognitive and motor function tests 5. the patient must have the ability to hear and follow a request. hearing aids can be worn. 6. patient or patient's legally authorized guardian(s) must provide signed, informed consent prior to performing any study-related activities (trial-related activities are any procedures that would not have been performed during normal management of the subject) 7. the patient and his/her guardian(s) must have the ability to comply with the protocol exclusion criteria: 1. the patient cannot walk without support. 2. presence of known chromosomal abnormality and syndromes affecting psychomotor development, other than alpha-mannosidosis 3. history of bone marrow transplantation 4. presence of known clinically significant cardiovascular, hepatic, pulmonary or renal disease or other medical conditions that, in the opinion of the investigator, would preclude participation in the trial 5. presence of an echo with abnormalities within half a year that, in the opinion of the investigator, would preclude participation in the trial 6. any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the investigator, would preclude participation in the trial 7. pregnancy 8. psychosis within the last 3 months
clinical study of 12-week trehalose intake in patients with fatty liver disease

Conditions: Non-alcoholic Fatty Liver

Summary: this clinical study will be conducted to evaluate the efficacy and safety of trehalose in patients with fatty liver disease. after 12-week intake, subjects will be checked up fat content in liver using ct scan.


Eligibility criteria:
inclusion criteria: * age between 19-year-old and 79-year-old * weight (≥50kg) * is diagnosed as fatty liver on ultrasonography within 24 weeks from screening day * has willingness and ability to participate whole clinical study period * willing to give informed consent form exclusion criteria: * patient with alcoholic fatty liver * patient with inflammatory bowel disease * is required treatment for like liver, kidney, digestive system, circulatory system, respiratory system, endocrine system(except diabetes), musculoskeletal, neuropsychiatry, or hemato-oncology etc., which is able to effect on clinical study * has any medical history with virus or toxic hepatitis * has any medical history of gastrointestinal surgery (except simple appendectomy \& repair of hernia) * has medical history of malignant tumor (except non-melanoma skin cancer) within the last 5 years from the screening day * took any drugs (udca, silymarin, omega-3, fenofibrate etc.) which is decided as unsuitable drug for combined-dose by investigator * over 4 times of maximum reference range of alt or ast * average drinking quantity per week \> alcohol 140 g * pregnant or nursing women * is currently participating into another clinical study * being made a decision from investigator as unsuitable to participate this study
assessing the bite counter

Conditions: Weight Loss

Summary: this study is designed to test the usability of the bite counter in an attempt to reduce participants' daily bites while also increasing their daily steps.

self-monitoring is an important component of behavioral management of obesity. the bite counter is a wrist-worn device which detects the motions characteristic of taking a bite of food or a drink of liquid, to provide the wearer with a cumulative count of bites and sips over the day. in earlier studies the method was shown to accurately count bites across a wide variety of foods, utensils and subject demographics, and to provide an unbiased intake measurement. the proposed work will continue to improve the bite counting method by adapting to varying eating rates, develop a self-managed bite count-based weight loss protocol, and perform an independent test of the protocol. an improved bite counter device will also measure activity (steps).

Eligibility criteria:
inclusion criteria: * participants must be between the ages of 18 and 70 (inclusive) * participants must have a bmi between 27 and 35 * participants must have regular and reliable access to a windows-based computer with an internet connection with usb connectivity * participants must be currently consuming at least 1400 calories per day * participants must demonstrate adequate compliance with using bite counter and uploading data during the two-week baseline period exclusion criteria: * participants must have no history of any eating disorder * participants must not have participated in a weight loss program within the month prior to baseline

Keywords: obesity weight loss
ultrasound guided intermediate cervical plexus block and additional perivascular local anesthetic infiltration

Conditions: Carotid Stenosis

Summary: for ultrasound guided intermediate cervical plexus block this randomized comparison is testing the hypothesis, that an additional perivascular infiltration is associated with increased block quality.

the innervation of the neck is complex and involves the cervical and the brachial plexus as well as cranial nerves. so is the wall of the carotid arteries innervated by vagal and glossopharyngeal nerve as well as the sympathetic trunk. when carotid surgery was performed under regional anesthesia, so additional infiltration of local anesthetic by the surgeon was common, particularly during preparation of the carotid arteries. introduction of ultrasound guidance made it possible to guide the needle directly to the vascular wall. but this procedure is considered very demanding, because of guiding the needle in an anatomical region with artifacts (because of calcification), sudden movements (e.g. because of swallowing) and compromised coagulation (antithrombotic medication). on the other side there are no clinical data proving the benefit of an additional perivascular infiltration with local anesthetic. therefore, this investigation is testing the hypothesis, that an additional perivascular infiltration is associated with increased block quality.

Eligibility criteria:
inclusion criteria: * carotid surgery (symptomatic and asymptomatic carotid stenosis) * adult patients (18 years or older) * asa-risk-groups i-iv * informed consent exclusion criteria: * drug allergy: local anesthetics * pregnancy, lactation period * participation in other studies * addiction to drugs or alcohol * non-cooperative patients * no approval to regional anesthesia

Keywords: cervical plexus regional anesthesia ultrasound carotid surgery
coffee after pancreatic surgery

Conditions: Postoperative Ileus; Postoperative Complications; Bowel Dysfunction; Pancreatic Diseases

Summary: postoperative ileus is a common complication after major abdominal surgery. a positive effect of coffee to bowel movement has been described after colorectal and gynecologic interventions. the objective of this randomised controlled trial is to investigate whether the implementation of a fast track protocol with early coffee consumption accelerates the recovery of bowel function after pancreaticoduodenectomy.

postoperative ileus (poi) is a common disorder after major abdominal surgery, affecting up to 40% of patients undergoing laparotomy. poi is described as the time between surgery and the first passage of flatus and/or stool and tolerance of oral diet. it could be recognised as postoperative complication when is defined as two or more of nausea/vomiting, inability to tolerate oral diet over 24 h, absence of flatus over 24 h, abdominal distention and radiologic confirmation on or after day 4 postoperatively without prior resolution. multimodal approaches have been described to treat poi; among them, the early consumption of coffee showed a substantial benefit after colorectal and gynecologic surgery. the objective of this randomised placebo-controlled trial is to investigate whether early coffee consumption can accelerate the recovery of bowel function after open pancreaticoduodenectomy.

Eligibility criteria:
inclusion criteria: * elective open pancreaticoduodenectomy * age ≥ 18 years * american society anesthesiologists (asa) score ≤ 3 * ability of the subject to understand aims and clinical consequences of the trial * written informed consent exclusion criteria: * american society anesthesiologists (asa) score ≥ 4 * need for early postoperative intensive care unit care * need for naso-gastric tube on postoperative day one * intolerance to coffee * refuse to assume coffee * pregnancy * surgical procedures performed different from pancreaticoduodenectomy * impaired mental status or language problems

Keywords: randomised clinical trial pancreatic surgery
metformin safety and efficacy in osteoarthritis.

Conditions: Osteo Arthritis Knee

Summary: knee osteoarthritis (oa) is a chronic, painful disease associated with considerable morbidity, costs and disability. it is estimated that over a third of people aged over 60 have radiographic knee oa2 and over 50% of these with knee oa will go on to have a total knee replacement in their lifetime. at present there are no licensed treatments that alter disease progress and management is primarily concerned with symptom control to retain or improve joint function, although a trial of strontium ranelate showed promising results.


Eligibility criteria:
inclusion criteria: * primary osteoarthritis patients recruited were between 30 to 60 years of age. * x-ray confirmed kellgren-lawrence grade ii or iii severity primary tibiofemoral oa according to the american college of rheumatology criteria. exclusion criteria: patients with age less than 30 years or more than 60 years patients presented with active concomitant gastroduodenal disorders, hepatic and renal impairment within last 30 days prior to receiving the study drug patients were diagnosed to have any inflammatory arthritis, gout or acute trauma of the knee, hip or spine; accompanying oa of the hip of sufficient severity to interfere with the functional assessment of the knee patients had previous or ongoing treatment with oral sysdoa (e.g., glucosamine sulphate, chondroitin sulphate, diacerein, piascledine), anti-depressants, tranquillisers, antacids or antibiotics; were having active cardiac lesion or hypertension, were pregnant females and those who were planning their pregnancy during the study patients having a known hypersensitivity to the used medications patients have persistent diarrhoea or laxative use; severe gastrointestinal disorders, severe obesity, severe parenchymal organ disease, or anaemia (haemoglobin\< 10.0 g/ dl or haematocrit \< 30%). patients who received oral, intramuscular, intraarticular or soft tissue injections of corticosteroids within last eight weeks before receiving the first dose of the study medication or had undergone joint lavage and arthroscopic procedures in the previous 6 months, were also excluded.
efficacy of sensory electrical stimulation versus alternating electromyogram (emg) on functional recovery of hand in chronic stroke survivors :randomized controlled trial

Conditions: Chronic Stroke Survivors; Chronic Stroke Survivors With Plegic Hand

Summary: this study aims to find out which treatment works better for improving hand function in stroke patients: sensory electrical stimulation or alternating electromyogram (emg) stimulation. both methods use electrical stimulation to help patients regain hand movement, but they work in slightly different ways. the goal is to see if one method is more effective than the other in helping stroke survivors recover their hand abilities.


Eligibility criteria:
inclusion criteria: * chronic stroke patients were between 45 and 65 years old, with a duration of illness ranging from 6 to 18 months post-stroke. they exhibited upper extremity spasticity no greater than 1+ on the modified ashworth scale. patients were cooperative, as indicated by a mini-mental state examination (mmse) score of ≥ 24, and were capable of grasping and releasing at least one block in the box and block test. exclusion criteria: * hand function impairment caused by factors other than stroke, unstable health conditions such as cardiac dysfunction, end-stage renal failure, or uncontrolled diabetes, long-term use of medications that may affect motor or sensory excitability, contractures or restrictions in wrist joint range of motion, pre-existing musculoskeletal diseases significantly impacting physical function, and a history of botulinum toxin injection in the hand muscles.

Keywords: sensory electrical stimulation - alternating electromyogram (emg) - functional recovery - hand - chronic stroke survivors
study on b-blockers to prevent decompensation of cirrhosis with htportal

Conditions: Portal Hypertension Gastropathy; Esophageal Varices; Spontaneous Bacterial Peritonitis; Hepatic Encephalopathy; Ascites

Summary: this is a multicenter, randomized, double-blind, placebo-controlled study on the effectiveness of treatment with beta-blockers to prevent decompensation of cirrhosis with portal hypertension.


Eligibility criteria:
inclusion criteria: * between 18 and 80 years old. * with liver cirrhosis diagnosed by previous biopsy or by clinical criteria, and analytical image. * no esophageal varices (or with small varices without red signs) in a recent videogastroscophy (\<3 months before randomization). * absence of ascites demonstrated by a recent ultrasound (\<3 months before the randomization). * informed consent exclusion criteria: * previous decompensation of liver cirrhosis associated with portal hypertension. * gpvh \<10 mmhg. * portal axis thrombosis affecting the portal trunk or main hepatic branches, or the splenic or mesenteric vein. * hepatocellular carcinoma demonstrated by two imaging tests. * bilirubin\> 3 mg / dl (or\> 50 micromol / l), platelets \<30 x10e9/lo quick \<30%. * presence of renal insufficiency (serum creatinine\> 2 mg / dl or\> 200 micromol / l). * any comorbidity involving a therapeutic limitation and / or a prognosis of life \<12 months. * absolute contraindication to treatment with β-blockers (severe bronchospasm, stenosis aortic a-v block, intermittent claudication, severe psychosis, bronchial asthma) * hypersensitivity to β-blockers. * pregnancy or lactation. * to receive anticoagulant treatment. * past treatment with nitrated or β-blockers in the two weeks prior inclusion. * cirrhosis c virus active antiviral therapy.
coaching intervention in women at-risk of common mental disorders

Conditions: Common Mental Disorder

Summary: this study aims to provide preventative intervention to 60 women who are at risk of common mental disorders in hong kong.

participants will be recruited through the following routes: 1) by our partner non-governmental organizations, 2) by our research team through community outreach or training activities, 3) online screening tool, and 4) referral from organizations that provide service to women (e.g., maternal and child health clinics of department of health). eligible subjects with informed consent provided will be randomly assigned to coaching group or sms self-help tips. to test the effectiveness of the provided intervention programs, symptoms assessments and data collection on demographics and psychosocial data will be carried out during baseline, immediately, and 3 months post-intervention.

Eligibility criteria:
inclusion criteria: * willing to provide written informed consent * able to understand cantonese and read/write chinese * with subsyndromal or minor depressive symptoms indicated by * depression subscale of depression, anxiety and stress scale (dass) score 10-20 or * edinburgh postnatal depression scale (epds) scores 10-13 exclusion criteria: * a positive response in items about suicidal thoughts if applicable ("yes, quite often" and "sometimes" in epds) (these participants will be referred to suicidal management) * those mental conditions that require other treatment priorities (e.g., suicidal risk, substance abuse, current or past episodes of psychotic disorder, personality disorders) * those medical conditions that severely limit participation, comprehension, or adherence to treatment (e.g., epilepsy, dementia, terminal medical illness) * those who are receiving structured psychotherapy or counseling